JACKSONVILLE, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) --

佛罗里达州杰克逊维尔，2026年10月8日（环球新闻社）--

MMI

人机界面

(Medical Microinstruments, Inc.), a robotics company dedicated to increasing treatment options and improving clinical outcomes for patients with complex conditions, today announced that it has raised $125 million in Series D financing.

（Medical Microinstruments, Inc.）是一家致力于增加复杂疾病患者的治疗选择并改善其临床结果的机器人公司，今日宣布已完成1.25亿美元的D轮融资。

The round was led by existing investor BioStar Capital, with participation from new investors S3 Ventures, Angelini Ventures, and an undisclosed strategic corporate investor. MMI’s existing investors also contributed, reflecting strong conviction in the company’s opportunity for continued growth and the expanding adoption of robotic microsurgery globally..

本轮融资由现有投资者 BioStar Capital 领投，新投资者 S3 Ventures、Angelini Ventures 以及一家未披露的战略企业投资者参与跟投。MMI 的现有投资者也进行了追加投资，这反映出他们对公司持续增长机遇以及机器人显微手术在全球范围内日益广泛应用的坚定信心。

The financing comes as MMI enters its next stage of growth, with approximately 50 installed systems and 3,500 complex microsurgical procedures performed worldwide using the

此次融资正值MMI进入下一增长阶段，其已在全球安装约50套系统，并利用该系统完成了3,500例复杂的显微外科手术。

Symani

西马尼

®

®

Surgical System

手术系统

. The capital will support MMI’s continued commercial expansion in the U.S. and key global markets, while strengthening the foundation needed to expand patient access. Investment in clinical trials and outcomes data, including the REMIND study, will also help expand the applications for Symani and support broader adoption..

这笔资金将支持MMI在美国及关键全球市场的持续商业扩张，同时夯实扩大患者可及性所需的基础。对临床试验和结果数据（包括REMIND研究）的投资也将有助于拓展Symani的应用范围并支持其更广泛的采用。

“We’ve proven there is demand for robotic microsurgery at leading institutions around the world. Now, our focus is translating that adoption into scale,” said Mark Toland, CEO of MMI. “This investment gives us the ability to expand our reach, accelerate adoption and continue advancing the platform through innovation in areas like energy instruments and digital surgery capabilities.”.

“我们已经证明，全球领先机构对机器人显微手术存在需求。现在，我们的重点是将这种采用转化为规模化应用。”MMI首席执行官马克·托兰表示，“这笔投资使我们能够扩大市场覆盖范围，加速技术采用，并通过在能量器械和数字手术能力等领域的创新，持续推动平台发展。”

Scaling Robotic Microsurgery and Advancing New Possibilities

规模化机器人显微外科并开拓新可能

MMI was founded to transform open surgery by extending the capabilities of surgeons at the microsurgical level. As adoption grows, MMI is working with innovation-driven hospitals to develop robotic microsurgery programs designed to bring the capabilities of Symani to more surgeons and patients in need of delicate cancer and trauma-related reconstructive surgery and lymphatic and nerve repair options that improve quality of life..

MMI 成立的宗旨是通过在显微外科层面拓展外科医生的能力，从而变革开放手术。随着应用范围的不断扩大，MMI 正与创新驱动的医院合作，开发机器人显微外科项目，旨在将 Symani 系统的能力惠及更多外科医生和患者，为需要精细的癌症及创伤相关重建手术以及淋巴管和神经修复治疗（以提升生活质量）的患者提供更多选择。

“We’re excited to lead the oversubscribed round of funding. MMI represents the pinnacle of what we look for at BioStar: a transformational medical technology with the potential to revolutionize patient care and then some,” said Louie Cannon, MD, founder and senior managing director of BioStar Capital.

“我们很高兴能领衔此次超额认购的融资轮。MMI 代表了 BioStar 所寻求的巅峰之作：一项具有变革性的医疗技术，不仅有望彻底革新患者护理，更蕴藏着超越预期的潜力。”BioStar Capital 创始人兼高级执行董事 Louie Cannon 医学博士表示。

“The most consequential innovations don’t simply improve upon what exists. They create capabilities medicine did not have before. MMI is already demonstrating that in cancer-related lymphedema, and as our scientific understanding of the lymphatic system continues to advance, we believe the company is only beginning to show what those capabilities could mean for patients.”.

“最具深远影响的创新并非仅仅对现有事物加以改进，而是创造出医学此前所不具备的能力。MMI 在癌症相关淋巴水肿领域已经证明了这一点。随着我们对淋巴系统的科学认识不断深入，我们相信该公司才刚刚开始展现这些能力将为患者带来的意义。”

“The greatest potential for this technology may ultimately lie in areas we are only beginning to investigate,” Toland added. “Through research like REMIND for Alzheimer’s disease, we’re building the evidence and clinical experience that could help define where robotic microsurgery goes next, and the opportunities are remarkable.”.

“这项技术的最大潜力最终可能存在于我们才刚刚开始探索的领域，”托兰补充道。“通过针对阿尔茨海默病的REMIND等研究，我们正在积累证据和临床经验，这将有助于明确机器人显微外科的下一步发展方向，其中的机遇令人瞩目。”

About Medical Microinstruments, Inc. (MMI)

关于 Medical Microinstruments, Inc. (MMI)

MMI is on a mission to advance robotic technology that pushes the limits of soft tissue open surgery and opens new opportunities for surgeons to restore quality of life for more patients with complex conditions. The company was founded in 2015 near Pisa, Italy, and its proprietary Symani

MMI 致力于推进机器人技术，突破软组织开放手术的极限，为外科医生开辟新机遇，帮助更多患有复杂疾病的患者恢复生活质量。该公司于2015年在意大利比萨附近成立，其专有技术 Symani

®

®

Surgical System combines the world’s smallest wristed microinstruments with tremor-reducing and motion-scaling technologies to address significant unmet patient needs across the globe. This first-of-its-kind surgical robotic platform for open, soft tissue micro-level surgery can help address microvascular repair and lymphatic repair.

该手术系统将全球最小的腕式显微器械与减颤和运动缩放技术相结合，旨在满足全球患者尚未被满足的重大医疗需求。作为首个用于开放式软组织显微手术的同类型手术机器人平台，它有助于解决微血管修复和淋巴修复问题。

In Europe and APAC, it also addresses peripheral nerve repair. The Symani System is authorized for use in the U.S. by the FDA and is a CE Marked medical device in Europe. MMI is backed by global investors including Andera Partners, Angelini Ventures, BioStar Capital, Deerfield Management, Fidelity Management & Research Company, Fountain Healthcare Partners, Panakès Partners, RA Capital, Sambatech, S3 Ventures, and Wellington Partners..

在欧洲和亚太地区，该系统也用于周围神经修复。Symani 系统已获得美国食品药品监督管理局（FDA）批准在美国使用，并在欧洲作为带有 CE 标志的医疗器械上市。MMI 得到全球投资者的支持，包括 Andera Partners、Angelini Ventures、BioStar Capital、Deerfield Management、富达管理与研究公司（Fidelity Management & Research Company）、Fountain Healthcare Partners、Panakès Partners、RA Capital、Sambatech、S3 Ventures 和 Wellington Partners。

Media Contact

媒体联系人

Laura Bastardi, MWW

劳拉·巴斯塔尔迪，MWW

mmi@mww.com

mmi@mww.com

Investor Relations Contact

投资者关系联系人

Lisa Croke

丽莎·克罗克

lisa.croke@mmimicro.com

lisa.croke@mmimicro.com